How to Use the Program

Practice completes a one-time registration by calling (855) 218-5307. At the time of enrollment, we also can:

The Provider administers the LUCENTIS treatment and collects the patient's co-pay for drug costs.

Fax a copy of or upload the detailed Explanation of Benefits (EOB)* to (855) 320-0457.

The requirements for reimbursement must include:

  • Name of insurance company
  • Facility name
  • Patient's name
  • Date of Service (DOS)
  • Name of drug or J-code
  • Amount billed, Amount allowed, Patient responsibility, Amount paid to provider

If the EOB does not include any of the above items, additional documentation may be required to process the claim.

The LUCENTIS Co-pay Program verifies the patient's information.
The Provider collects the remainder of the patient's out-of-pocket (OOP) drug costs via Electronic Funds Transfer (EFT) or check reimbursement.

*EOBs must be submitted within 365 days from the date of service (DOS) for consideration.

Important Safety Information & Indication


LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:

  • Neovascular (wet) age-related macular degeneration (wAMD)
  • Macular edema following retinal vein occlusion (RVO)
  • Diabetic macular edema (DME)
  • Diabetic retinopathy (DR)
  • Myopic choroidal neovascularization (mCNV)


LUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.

Increases in intraocular pressure have been noted both pre-injection and post-injection with LUCENTIS.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555.

For additional safety information, please see LUCENTIS full prescribing information.